Related Experiment Video
Updated: May 7, 2026

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
Published on: March 12, 2013
Development of heart failure is independent of K+ channel-interacting protein 2 expression
Tobias Speerschneider1, Søren Grubb, Artina Metoska
1M. B. Thomsen: Danish National Research Foundation Centre for Cardiac Arrhythmia, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 3b Blegdamsvej, building 12.5.36, Copenhagen N, Denmark. mbthom@sund.ku.dk.
Insights
Reduced KChIP2 expression in heart failure (HF) does not cause HF but lowers arrhythmia susceptibility. Downregulation of KChIP2 in HF may be antiarrhythmic by reducing the transient outward K(+) current.
Area of Science:
- Cardiology
- Molecular Biology
- Electrophysiology
Background:
- Abnormal ventricular repolarization is a key factor in arrhythmias and sudden cardiac death.
- K(+) channel-interacting protein 2 (KChIP2) expression decreases in heart failure (HF), reducing the transient outward K(+) current (Ito).
Purpose of the Study:
- To investigate the role of KChIP2 expression changes in HF development and proarrhythmia.
- To determine if KChIP2 downregulation contributes to HF or affects arrhythmia susceptibility.
Main Methods:
- Created heart failure in wild-type (WT) and KChIP2(-/-) mice using transverse aortic constriction (TAC).
- Monitored cardiac function via echocardiography and recorded ECGs.
- Induced arrhythmias through in vivo heart pacing and analyzed ventricular tissue.
Main Results:
- HF development was similar in WT and KChIP2(-/-) mice post-TAC.
- KChIP2 expression decreased significantly in WT mice with HF.
- KChIP2(-/-) mice, with or without HF, showed reduced susceptibility to pacing-induced ventricular tachycardia (VT).
Conclusions:
- KChIP2 downregulation is not the driver of HF development.
- KChIP2 influences ventricular repolarization and decreases arrhythmia risk.
- Reduced KChIP2 in HF might be an antiarrhythmic mechanism by decreasing Ito.
Abstract:
Abnormal ventricular repolarization in ion channelopathies and heart disease is a major cause of ventricular arrhythmias and sudden cardiac death. K(+) channel-interacting protein 2 (KChIP2) expression is significantly reduced in human heart failure (HF), contributing to a loss of the transient outward K(+) current (Ito). We aim to investigate the possible significance of a changed KChIP2 expression on the development of HF and proarrhythmia. Transverse aortic constrictions (TAC) and sham operations were performed in wild-type (WT) and KChIP2(-/-) mice. Echocardiography was performed before and every 2 weeks after the operation. Ten weeks post-surgery, surface ECG was recorded and we paced the heart in vivo to induce arrhythmias. Afterwards, tissue from the left ventricle was used for immunoblotting. Time courses of HF development were comparable in TAC-operated WT and KChIP2(-/-) mice. Ventricular protein expression of KChIP2 was reduced by 70% after 10 weeks TAC in WT mice. The amplitudes of the J and T waves were enlarged in KChIP2(-/-) control mice. Ventricular effective refractory period, RR, QRS and QT intervals were longer in mice with HF compared to sham-operated mice of either genotype. Pacing-induced ventricular tachycardia (VT) was observed in 5/10 sham-operated WT mice compared with 2/10 HF WT mice with HF. Interestingly, and contrary to previously published data, sham-operated KChIP2(-/-) mice were resistant to pacing-induced VT resulting in only 1/10 inducible mice. KChIP2(-/-) with HF mice had similar low vulnerability to inducible VT (1/9). Our results suggest that although KChIP2 is downregulated in HF, it is not orchestrating the development of HF. Moreover, KChIP2 affects ventricular repolarization and lowers arrhythmia susceptibility. Hence, downregulation of KChIP2 expression in HF may be antiarrhythmic in mice via reduction of the fast transient outward K(+) current.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure Drugs: Diuretics
Heart Failure I: Introduction
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure IV: Classification and Diagnostic Evaluation

